Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 472 of 6351
-
AI picks who gets a second chance at targeted breast cancer therapy
Disease control Recruiting nowThe goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patient…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Scan-Guided radiation aims to cut side effects in recurrent prostate cancer
Disease control Recruiting nowPurpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining cancer control after prostatectomy.Population/Eligibility: Adult men ≥30 years with…
Phase 2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New triple therapy offers hope for hard-to-treat nose and throat cancer
Disease control Not yet recruitingTo explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereb…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to stop breast cancer return in women with gene mutations
Disease control Not yet recruitingThe study is a randomized, open-label, multicenter phase II clinical trial of the efficacy and safety of fluzopanib in the adjuvant treatment of early breast cancer using germline mutations in homologous recombination repair pathway genes. Study design Patients will be randomized…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Radiation boosts cancer drug in Tough-to-Treat myeloma
Disease control Recruiting nowTo learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy aims to control advanced lung cancer
Disease control Recruiting nowThis is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination wi…
Phase 1/2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could shrink nerve tumors in NF1 patients
Disease control Recruiting nowThis study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
Disease control Not yet recruitingThis is a prospective, multicenter, open-label, randomized, controlled Study. The purpose of this study is to evaluate the efficacy and safety of SHR-A1811 versus pyrotinib plus capecitabine in the treatment of trastuzumab primary-resistant HER2-positive advanced breast cancer.
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Stroke patients may get faster lifesaving care by skipping standard scans
Disease control Not yet recruitingThe investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MR…
Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New triple therapy aims to shrink pancreatic tumors before surgery
Disease control Not yet recruitingThe goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic cancer. It will also learn about the safety of the …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Promising combo therapy shows hope for Hard-to-Treat bile duct cancer
Disease control Recruiting nowBiliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patien…
Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New triple-drug combo aims to keep advanced breast cancer in check
Disease control Not yet recruitingThis is a Prospective, Single-Arm, Observational, Real-World Study. The purpose of this study is to evaluate the safety and efficacy of pyrotinib combined with trastuzumab and pertuzumab for maintenance therapy in HER2-positive advanced breast cancer in the real-world setting.
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for elderly AML patients: drug combo aims to control disease without harsh chemo
Disease control Not yet recruitingThis study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled. The Simon two-stage design will be adopted to control the t…
Phase 2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New obesity drug HDM1005 takes on tirzepatide in head-to-head trial
Disease control Recruiting nowThis is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzep…
Phase 2 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for aggressive lymphoma: targeted combo trial launches
Disease control Not yet recruitingEvaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Phase 3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Massive cancer DNA hunt aims to stop relapse before it starts
Knowledge-focused Recruiting nowThis study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for earl…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
One procedure to fix rhythm and block clots: new study tests dual approach for AFib
Disease control Recruiting nowThe objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in patients indicated for both AF ablation and percutaneous LAAO.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
MRI brain scan could prevent unnecessary stroke surgeries
Disease control Recruiting nowNarrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For l…
Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThe purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
Phase 2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control Ongoingan open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of SIM0532 in participants with advanced solid tumors. The study commences with a dose-escalation part (Part 1), followe…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC